DRUG
Bright Minds Biosciences Inc.
Biotechnology
Market Cap$864M
5Y Perf.+286.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DRUG vs ATAI
Revenue, margins, valuation, and 5-year total return — side by side.
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$964M
5Y Perf.-78.3%
DRUG vs ATAI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DRUG | ATAI |
|---|---|---|
| Industry | Biotechnology | Medical - Pharmaceuticals |
| Market Cap | $864M | $964M |
| Revenue (TTM) | $0.00 | $3M |
| Net Income (TTM) | $-11M | $-154M |
| Gross Margin | — | -259.1% |
| Operating Margin | — | -34.6% |
| Total Debt | $126K | $25M |
| Cash & Equiv. | $83M | $18M |
DRUG vs ATAI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DRUG
ATAI
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Bright Minds Biosci… (DRUG) | 100 | 386.0 | +286.0% |
| Atai Beckley N.V (ATAI) | 100 | 21.7 | -78.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DRUG vs ATAI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DRUG leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Atai Beckley N.V is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
DRUG
Bright Minds Biosciences Inc.
The Growth Play
DRUG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth -96.9%
- 228.9% 10Y total return vs ATAI's -47.7%
- Lower volatility, beta 1.87, Low D/E 0.2%, current ratio 36.10x
Best for: growth exposure and long-term compounding
ATAI
Atai Beckley N.V
The Income Pick
ATAI is the clearest fit if your priority is income & stability and defensive.
- beta 1.48
- Beta 1.48, current ratio 3.21x
- -1.9% revenue growth vs DRUG's -305.3%
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATAI | -1.9% revenue growth vs DRUG's -305.3% |
| Quality / Margins | DRUG | 1.3% margin vs ATAI's -51.1% |
| Stability / Safety | ATAI | Beta 1.48 vs DRUG's 1.87 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DRUG | +195.1% vs ATAI's +188.5% |
| Efficiency (ROA) | DRUG | -13.1% ROA vs ATAI's -64.3% |
DRUG vs ATAI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
DRUG vs ATAI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDRUGLAGGINGATAI
ATAIAtai Beckley N.V
1leads
DRUGBright Minds Bioscien…
2leads
6 Total Categories
CATEGORYLEADERvs ATAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATAI1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DRUG7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DRUG6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATAI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATAI and DRUG operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | DRUGBright Minds Bios… | ATAIAtai Beckley N.V |
|---|---|---|
| RevenueTrailing 12 months | $0 | $3M |
| EBITDAEarnings before interest/tax | -$12M | -$103M |
| Net IncomeAfter-tax profit | -$11M | -$154M |
| Free Cash FlowCash after capex | -$8M | -$90M |
| Gross MarginGross profit ÷ Revenue | — | -2.6% |
| Operating MarginEBIT ÷ Revenue | — | -34.6% |
| Net MarginNet income ÷ Revenue | — | -51.1% |
| FCF MarginFCF ÷ Revenue | — | -29.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -141.2% | -75.0% |
ATAI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — DRUG and ATAI each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | DRUGBright Minds Bios… | ATAIAtai Beckley N.V |
|---|---|---|
| Market CapShares × price | $864M | $964M |
| Enterprise ValueMkt cap + debt − cash | $804M | $971M |
| Trailing P/EPrice ÷ TTM EPS | -94.67x | -4.31x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3130.37x |
| Price / BookPrice ÷ Book value/share | 10.16x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — DRUG and ATAI each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DRUG leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
DRUG delivers a -13.5% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-96 for ATAI. DRUG carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATAI's 0.21x. On the Piotroski fundamental quality scale (0–9), DRUG scores 4/9 vs ATAI's 2/9, reflecting mixed financial health.
| Metric | DRUGBright Minds Bios… | ATAIAtai Beckley N.V |
|---|---|---|
| ROE (TTM)Return on equity | -13.5% | -96.4% |
| ROA (TTM)Return on assets | -13.1% | -64.3% |
| ROICReturn on invested capital | — | -45.0% |
| ROCEReturn on capital employed | -31.8% | -50.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.00x | 0.21x |
| Net DebtTotal debt minus cash | -$83M | $7M |
| Cash & Equiv.Liquid assets | $83M | $18M |
| Total DebtShort + long-term debt | $125,777 | $25M |
| Interest CoverageEBIT ÷ Interest expense | -541.45x | -68.93x |
DRUG leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DRUG leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DRUG five years ago would be worth $38,216 today (with dividends reinvested), compared to $2,016 for ATAI. Over the past 12 months, DRUG leads with a +195.1% total return vs ATAI's +188.5%. The 3-year compound annual growth rate (CAGR) favors DRUG at 2.1% vs ATAI's 25.9% — a key indicator of consistent wealth creation.
| Metric | DRUGBright Minds Bios… | ATAIAtai Beckley N.V |
|---|---|---|
| YTD ReturnYear-to-date | +6.4% | +3.6% |
| 1-Year ReturnPast 12 months | +195.1% | +188.5% |
| 3-Year ReturnCumulative with dividends | +2860.5% | +99.5% |
| 5-Year ReturnCumulative with dividends | +282.2% | -79.8% |
| 10-Year ReturnCumulative with dividends | +228.9% | -47.7% |
| CAGR (3Y)Annualised 3-year return | +2.1% | +25.9% |
DRUG leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DRUG and ATAI each lead in 1 of 2 comparable metrics.
Risk & Volatility
ATAI is the less volatile stock with a 1.48 beta — it tends to amplify market swings less than DRUG's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DRUG currently trades 71.8% from its 52-week high vs ATAI's 59.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DRUGBright Minds Bios… | ATAIAtai Beckley N.V |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.48x |
| 52-Week HighHighest price in past year | $123.75 | $6.75 |
| 52-Week LowLowest price in past year | $23.18 | $1.29 |
| % of 52W HighCurrent price vs 52-week peak | +71.8% | +59.4% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 51.5 |
| Avg Volume (50D)Average daily shares traded | 156K | 6.0M |
Evenly matched — DRUG and ATAI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DRUG as "Buy" and ATAI as "Buy". Consensus price targets imply 199.3% upside for ATAI (target: $12) vs 53.7% for DRUG (target: $137).
| Metric | DRUGBright Minds Bios… | ATAIAtai Beckley N.V |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $136.50 | $12.00 |
| # AnalystsCovering analysts | 3 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DRUG leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ATAI leads in 1 (Income & Cash Flow). 2 tied.
Best OverallBright Minds Biosciences In… (DRUG)Leads 2 of 6 categories
Loading custom metrics...
DRUG vs ATAI: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DRUG or ATAI a better buy right now?
Analysts rate Bright Minds Biosciences Inc.
(DRUG) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DRUG or ATAI?
Over the past 5 years, Bright Minds Biosciences Inc.
(DRUG) delivered a total return of +282. 2%, compared to -79. 8% for Atai Beckley N. V (ATAI). Over 10 years, the gap is even starker: DRUG returned +228. 9% versus ATAI's -47. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DRUG or ATAI?
By beta (market sensitivity over 5 years), Atai Beckley N.
V (ATAI) is the lower-risk stock at 1. 48β versus Bright Minds Biosciences Inc. 's 1. 87β — meaning DRUG is approximately 26% more volatile than ATAI relative to the S&P 500. On balance sheet safety, Bright Minds Biosciences Inc. (DRUG) carries a lower debt/equity ratio of 0% versus 21% for Atai Beckley N. V — giving it more financial flexibility in a downturn.
04Which is growing faster — DRUG or ATAI?
On earnings-per-share growth, the picture is similar: Bright Minds Biosciences Inc.
grew EPS -96. 9% year-over-year, compared to -272. 0% for Atai Beckley N. V. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DRUG or ATAI?
Bright Minds Biosciences Inc.
(DRUG) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DRUG leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DRUG or ATAI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DRUG or ATAI better for a retirement portfolio?
For long-horizon retirement investors, Atai Beckley N.
V (ATAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Bright Minds Biosciences Inc. (DRUG) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATAI: -47. 7%, DRUG: +228. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DRUG and ATAI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.